DE60325354D1 - Topisch anwendbare pharmazeutische zubereitung - Google Patents

Topisch anwendbare pharmazeutische zubereitung

Info

Publication number: DE60325354D1
Authority: DE; Germany
Prior art keywords: pharmaceutical preparation; topic; applicable pharmaceutical; applicable; administering
Prior art date: 2002-05-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60325354T

Other languages

English (en)

Inventor

Christina Bolle

Rudolf Linder

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda GmbH

Original Assignee

Nycomed GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-28

Filing date

2003-05-27

Publication date

2009-01-29

2003-05-27 Application filed by Nycomed GmbH filed Critical Nycomed GmbH

2009-01-29 Application granted granted Critical

2009-01-29 Publication of DE60325354D1 publication Critical patent/DE60325354D1/de

2023-05-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dispersion Chemistry (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DE60325354T 2002-05-28 2003-05-27 Topisch anwendbare pharmazeutische zubereitung Expired - Lifetime DE60325354D1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP02011830		2002-05-28
DE10223828		2002-05-28
DE10311613		2003-03-14
PCT/EP2003/005524 WO2003099334A1 (en)	2002-05-28	2003-05-27	Topically applicable pharmaceutical preparation

Publications (1)

Publication Number	Publication Date
DE60325354D1 true DE60325354D1 (de)	2009-01-29

Family

ID=29587313

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE60334692T Expired - Lifetime DE60334692D1 (de)	2002-05-28	2003-05-27	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
DE60325354T Expired - Lifetime DE60325354D1 (de)	2002-05-28	2003-05-27	Topisch anwendbare pharmazeutische zubereitung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE60334692T Expired - Lifetime DE60334692D1 (de)	2002-05-28	2003-05-27	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen

Country Status (33)

Country	Link
US (7)	US20060084685A1 (de)
EP (3)	EP2020243B1 (de)
JP (3)	JP2005529928A (de)
KR (2)	KR20050014844A (de)
CN (3)	CN1655823B (de)
AT (2)	ATE485821T1 (de)
AU (2)	AU2003232828B2 (de)
BR (2)	BR0311337A (de)
CA (2)	CA2486917C (de)
CY (2)	CY1110312T1 (de)
DE (2)	DE60334692D1 (de)
DK (3)	DK1511481T3 (de)
EA (2)	EA010416B1 (de)
ES (3)	ES2693094T3 (de)
HK (2)	HK1079437A1 (de)
HR (1)	HRP20041211B1 (de)
HU (1)	HUE039709T2 (de)
IL (3)	IL164935A (de)
IS (1)	IS2639B (de)
LT (1)	LT2020243T (de)
MA (1)	MA27813A1 (de)
ME (1)	ME00565A (de)
MX (2)	MXPA04011612A (de)
NO (2)	NO334882B1 (de)
NZ (3)	NZ553731A (de)
PL (3)	PL397021A1 (de)
PT (3)	PT1511481E (de)
RS (1)	RS51104B (de)
SI (2)	SI2020243T1 (de)
TR (1)	TR201815573T4 (de)
UA (2)	UA88523C2 (de)
WO (2)	WO2003099334A1 (de)
ZA (2)	ZA200408649B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872382B1 (en)	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) *	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
NZ553731A (en) *	2002-05-28	2007-07-27	Altana Pharma Ag	Topically applicable pharmaceutical preparation of roflumilast and liquid paraffin
EP1542768A1 (de)	2002-09-20	2005-06-22	Alcon, Inc.	Verwendung von zytokin-synthesehemmern zur behandlung von erkrankungen mit trockenem auge
FR2851247B1 (fr)	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
ME00524B (me)	2003-03-10	2011-10-10	Astrazeneca Ab	Novi postupak za dobijanje roflumilasta
US20070082017A1 (en) *	2004-01-10	2007-04-12	Tseng Scheffer C	Lipid compositions and methods of use
DE102004046235A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
DE102004046236A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
US8017633B2 (en)	2005-03-08	2011-09-13	Nycomed Gmbh	Roflumilast for the treatment of diabetes mellitus
WO2006097456A1 (en) *	2005-03-16	2006-09-21	Nycomed Gmbh	Taste masked dosage form containing roflumilast
US20090209599A1 (en) *	2005-06-09	2009-08-20	Yoko Endo	Eye drop containing roflumilast
PL1992622T3 (pl)	2006-02-21	2012-01-31	Eisai R&D Man Co Ltd	Pochodna 4-(3-benzoiloaminofenylo)-6,7-dimetoksy-2-metyloaminochinazoliny
EP2123641A4 (de)	2007-02-16	2011-06-22	Eisai R&D Man Co Ltd	Kristall, amorphe form und salt von methyl n-[3-(6,7-dimethoxy- 2-methylaminochinazolin-4-yl)phenyl]terephthalamsäure
ATE538102T1 (de)	2007-08-17	2012-01-15	Eisai R&D Man Co Ltd	Verfahren zur herstellung eines chinazolinderivats
WO2009025239A1 (ja)	2007-08-17	2009-02-26	Eisai R & D Management Co., Ltd.	新規外用剤
JP6071554B2 (ja)	2009-10-30	2017-02-01	ネステクソシエテアノニム	イヌ科動物の眼の健康を維持するため、及び眼の病気を改善するための方法
ES2377785B2 (es)	2010-09-08	2012-09-26	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento del ojo seco.
ES2408132B1 (es) *	2010-09-08	2014-04-04	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento de la epífora.
ES2711100T3 (es) *	2011-03-07	2019-04-30	Celgene Corp	Métodos para tratar enfermedades usando compuestos isoindolina
CN102793684B (zh) *	2011-05-26	2016-02-17	杭州赛利药物研究所有限公司	罗氟司特液体制剂及其制备方法
WO2013000917A1 (en) *	2011-06-28	2013-01-03	Bayer Intellectual Property Gmbh	Topical ophthalmological pharmaceutical composition containing regorafenib
EP2836240B1 (de) *	2012-04-10	2019-03-13	Georgia State University Research Foundation, Inc.	Zusammensetzungen und verfahren zur behandlung von mittelohrentzündung und anderen erkrankungen mit cyld-inhibitoren
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
CN103570610B (zh) *	2012-07-18	2017-08-11	重庆华邦制药有限公司	一种罗氟司特微粒的制备方法
JP6434416B2 (ja)	2012-11-08	2018-12-05	ライゼン・ファーマシューティカルズ・エスアー	ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
EP3033082B1 (de)	2013-08-16	2021-06-16	Universiteit Maastricht	Behandlung von kognitiven störungen mit einem pde4-inhibitor
CN105434328A (zh) *	2014-09-01	2016-03-30	天津药物研究院有限公司	一种含罗氟司特固体分散体的固体制剂及其制备方法
JP5938537B1 (ja) *	2014-10-24	2016-06-22	久光製薬株式会社	プロドラッグ
CN104997959A (zh) *	2015-08-21	2015-10-28	蔡宇平	一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) *	2016-07-11	2019-10-01	赵晨	一种遗传性Usher综合征的致病突变及其检测试剂
US11129818B2 (en)	2017-06-07	2021-09-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en)	2017-06-07	2024-06-18	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en)	2017-06-07	2021-06-03	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en)	2017-06-07	2018-02-20	Arcutis, Inc.	Inhibition of crystal growth of roflumilast
US20200155524A1 (en) *	2018-11-16	2020-05-21	Arcutis, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en)	2017-09-22	2022-12-27	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) *	2018-03-13	2018-07-17	兆科药业（广州）有限公司	一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
AU2019281888B2 (en) *	2018-06-04	2024-05-02	Arcutis Biotherapeutics, Inc.	Method and formulation for improving roflumilast skin penetration lag time
KR102117525B1 (ko) *	2018-07-09	2020-06-01	건양대학교 산학협력단	Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
CN115551478A (zh)	2020-01-31	2022-12-30	阿尔库缇斯生物疗法股份有限公司	具有改善递送和血浆半衰期的罗氟司特局部制剂
CA3153934C (en) *	2020-05-07	2023-01-31	David W. Osborne	Treatment of skin conditions using high krafft temperature anionic surfactants
WO2022169615A1 (en)	2021-02-05	2022-08-11	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
WO2022173923A1 (en) *	2021-02-10	2022-08-18	Iolyx Therapeutics, Inc.	Methods for ophthalmic delivery of roflumilast
CN116867480A (zh) *	2021-02-10	2023-10-10	洛利克斯治疗有限公司	眼部递送罗氟司特的方法
AU2022286942A1 (en) *	2021-06-01	2023-12-14	Eyedea Bio, Llc	Extended release drug delivery system for ocular drugs and methods of use
AU2022353032A1 (en) *	2021-09-22	2024-03-28	Iolyx Therapeutics, Inc.	Methods of treating ocular inflammatory diseases
US20240108609A1 (en)	2022-09-15	2024-04-04	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753945A (en) *	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) *	1988-05-31	1991-04-30	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) *	1992-09-14	1999-04-06	Wolf-Georg Forssmann	Use of inhibitors of phosphodiesterase IV
ES2176252T3 (es) *	1993-07-02	2002-12-01	Altana Pharma Ag	Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
KR960703621A (ko) *	1993-08-10	1996-08-31	후지야마 아키라	경피흡수 제제(Percutaneously absorbable preparation)
ZA954599B (en) *	1994-06-07	1996-01-26	Allergan Inc	Stable gel formulation for topical treatment of skin conditions
EP1118615A4 (de) *	1998-09-29	2002-02-27	Fujisawa Pharmaceutical Co	Salze von pyridopyrazinderivaten und kristalle davon
US6395746B1 (en) *	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) *	1998-10-13	2002-01-17	John Kung	Composition to enhance permeation of topical skin agents
US6531493B1 (en)	1999-03-10	2003-03-11	Altana Pharma Ag	3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
DZ3249A1 (fr) *	1999-10-29	2001-05-10	Smithkline Beecham Corp	Procédé d'administration d'un inhibiteur phosphodiesterase 4
CZ20022413A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
AU2001238288A1 (en) *	2000-02-16	2001-08-27	University Of Nebraska Medical Center	Method and compositions for treating fibrotic diseases
AU6196201A (en) *	2000-05-25	2001-12-03	Merck Frosst Canada Inc	Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
AU2002227123A1 (en) *	2000-11-07	2002-05-21	Merck And Co., Inc.	Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) *	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) *	2001-11-09	2003-05-15	Johannes Barsig	Combination
NZ553731A (en) *	2002-05-28	2007-07-27	Altana Pharma Ag	Topically applicable pharmaceutical preparation of roflumilast and liquid paraffin

2003
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Application Discontinuation
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/de not_active Expired - Lifetime
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en active Application Filing
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
- 2003-05-27 EP EP03730122A patent/EP1511481B1/de not_active Expired - Lifetime
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active IP Right Cessation
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en active Application Filing
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 EP EP03755048A patent/EP1511516B1/de not_active Expired - Lifetime
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
- 2004-12-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
2005
- 2005-12-14 HK HK05111481.8A patent/HK1079437A1/xx not_active IP Right Cessation
- 2005-12-16 HK HK05111628.2A patent/HK1079445A1/xx not_active IP Right Cessation
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003240719B2 (en)	2009-12-10
EA200401517A1 (ru)	2005-06-30
NO334882B1 (no)	2014-06-30
CN1655782A (zh)	2005-08-17
ZA200409584B (en)	2006-05-31
RS101404A (en)	2007-02-05
CA2486910C (en)	2011-11-29
KR20050014844A (ko)	2005-02-07
ME00565A (en)	2011-12-20
DK1511481T3 (da)	2011-01-24
HUE039709T2 (hu)	2019-01-28
CN1655823A (zh)	2005-08-17
CA2486910A1 (en)	2003-12-04
EP1511516A1 (de)	2005-03-09
CN101491520B (zh)	2011-03-16
SI1511516T1 (sl)	2009-06-30
IL165065A (en)	2010-11-30
UA88523C2 (ru)	2009-10-26
PT1511516E (pt)	2009-02-20
CN101491520A (zh)	2009-07-29
WO2003099278A1 (en)	2003-12-04
ES2354971T3 (es)	2011-03-21
TR201815573T4 (tr)	2018-11-21
UA81910C2 (uk)	2008-02-25
ES2693094T3 (es)	2018-12-07
BR0311339A (pt)	2005-03-22
IL164935A (en)	2010-12-30
JP5683538B2 (ja)	2015-03-11
NO334916B1 (no)	2014-07-14
ATE417628T1 (de)	2009-01-15
WO2003099334A1 (en)	2003-12-04
US20140303215A1 (en)	2014-10-09
IL209657A0 (en)	2011-02-28
IS2639B (is)	2010-06-15
NO20045506L (no)	2004-12-16
KR101307093B1 (ko)	2013-09-11
CN100490804C (zh)	2009-05-27
CN1655823B (zh)	2010-05-26
IL165065A0 (en)	2005-12-18
ATE485821T1 (de)	2010-11-15
SI2020243T1 (sl)	2018-11-30
US20110313005A1 (en)	2011-12-22
EP1511481A1 (de)	2005-03-09
PL212134B1 (pl)	2012-08-31
CY1121133T1 (el)	2019-12-11
CA2486917A1 (en)	2003-12-04
PL372095A1 (en)	2005-07-11
JP5652983B2 (ja)	2015-01-14
MA27813A1 (fr)	2006-04-03
HK1079437A1 (en)	2006-04-07
EP1511481B1 (de)	2010-10-27
EA020569B1 (ru)	2014-12-30
HK1079445A1 (en)	2006-04-07
PL372082A1 (en)	2005-07-11
HRP20041211A2 (hr)	2006-04-30
ZA200408649B (en)	2007-12-27
AU2003232828B2 (en)	2010-06-24
MXPA04011528A (es)	2005-02-14
NZ537308A (en)	2009-09-25
PT1511481E (pt)	2011-01-14
PL211870B1 (pl)	2012-07-31
CA2486917C (en)	2011-11-22
NZ553731A (en)	2007-07-27
AU2003232828A1 (en)	2003-12-12
BR0311337A (pt)	2005-03-15
AU2003240719A1 (en)	2003-12-12
EA200702588A1 (ru)	2008-08-29
US20060084684A1 (en)	2006-04-20
US20210116207A1 (en)	2021-04-22
ES2319517T3 (es)	2009-05-08
EA010416B1 (ru)	2008-08-29
IS7612A (is)	2004-12-23
US20080280958A1 (en)	2008-11-13
MXPA04011612A (es)	2005-03-07
US20060084685A1 (en)	2006-04-20
KR20110122230A (ko)	2011-11-09
EP2020243B1 (de)	2018-08-15
PL397021A1 (pl)	2012-03-26
PT2020243T (pt)	2018-11-09
DK1511516T3 (da)	2009-04-06
NO20045656L (no)	2004-12-27
EP2020243A1 (de)	2009-02-04
RS51104B (sr)	2010-10-31
IL164935A0 (en)	2005-12-18
LT2020243T (lt)	2018-11-12
HRP20041211B1 (hr)	2013-06-30
JP2005529928A (ja)	2005-10-06
NZ536920A (en)	2007-04-27
DE60334692D1 (de)	2010-12-09
JP2005529930A (ja)	2005-10-06
EP1511516B1 (de)	2008-12-17
DK2020243T3 (en)	2018-11-19
JP2012229245A (ja)	2012-11-22
CY1110312T1 (el)	2015-01-14
US20190029956A1 (en)	2019-01-31

Legal Events

Date	Code	Title	Description
2010-01-07	8364	No opposition during term of opposition

Publication	Publication Date	Title
CY1121133T1 (el)	2019-12-11	Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
GB0029562D0 (en)	2001-01-17	Organic compounds
UA84266C2 (uk)	2008-10-10	Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
AU2002211863A1 (en)	2002-04-15	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
ATE516017T1 (de)	2011-07-15	Feste pharmazeutische dosierform enthaltende ritonavir
ATE337016T1 (de)	2006-09-15	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
ECSP045447A (es)	2005-01-28	Preparación farmacéutica que se puede aplicar por vía tópica
ITMI931104A1 (it)	1994-11-28	Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo